Boehringer's Spiriva approved for asthma in EU, but expectations limited
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's Spiriva (tiotropium bromide) has been approved in the EU as an add-on treatment for adult patients with asthma – making it the first long-acting muscarinic antagonist (LAMA) to receive approval in the region for this indication.